Clinical effect of Cetuximab combined with FOLFOXIRI regimen in the treatment of liver metastasis of unresectable colorectal cancer
LU Ruimin1,2 LIU Tao2 WANG Xinji2 LI Jianguo2 LIANG Yao3 LUO Lijie1
1.Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Province, Guangzhou 510120, China;
2.Department of Anus and Intestine Surgery, University of Chinese Academy of Sciences Shenzhen Hospital (Guangming), Guangdong Province, Shenzhen 518107, China;
3.Department of Clinical Pharmacy, University of Chinese Academy of Sciences Shenzhen Hospital (Guangming), Guangdong Province, Shenzhen 518107, China
Abstract：Objective To investigate the clinical effect of Cetuximab combined with FOLFOXIRI regimen in the treatment of liver metastasis of unresectable colorectal cancer. Methods From January 2013 to May 2016, 105 patients with liver metastasis of unresectable colorectal cancer admitted to the Second Affiliated Hospital of Guangzhou University of Chinese Medicine were divided into the control group (52 cases) and the observation group (53 cases) according to the random number table method. The control group was treated with FOLFOXIRI regimen, while the observation group was treated with Cetuximab combined with FOLFOXIRI regimen. 14 days were one chemotherapy cycle. Both groups were given continuous treatment for 4 chemotherapy cycles. The clinical effect was evaluated after treatment. The number and size of lesions and the levels of peripheral blood CD4+, CD8+, CD4+/CD8+, serum glycoantigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) of patients in two groups were compared between before and after treatment. Survival rates of patients at 6 months, 1 year, and 3 years after treatment were calculated and compared between the two groups. Results The effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). The number and size of lesions of patients in both groups after treatment were significantly smaller than before treatment, and those in the observation group were significantly smaller than those in the control group, with statistically significant differences (all P ＜ 0.05). The levels of CD4+, CD8+ and CD4+/CD8+ in peripheral blood of patients in the two groups after treatment were significantly higher than those before treatment, and those in the observation group were significantly higher than those in the control group, with statistically significant differences (all P ＜ 0.05). Serum CA19-9 and CEA levels of patients in both groups after treatment were significantly lower than those before treatment, and those in the observation group were significantly lower than those in the control group, with statistically significant differences (all P ＜ 0.05). There was no significant difference in survival rate of patients between the two groups at 6 months after treatment (P ＞ 0.05). The 1 year and 3 year survival rates in the observation group after treatment were significantly higher than those in the control group, with statistically significant differences (all P ＜ 0.05). Conclusion Cetuximab combined with FOLFOXIRI regimen has a significant clinical effect in the treatment of liver metastasis of unresectable colorectal cancer, which can improve the immune function of the body, reduce serum CA19-9 and CEA levels, and prolong the survival time of patients.
卢锐敏1,2 刘涛2 王心吉2 李建国2 梁瑶3 罗立杰1. 西妥昔单抗联合FOLFOXIRI方案治疗不可切除结直肠癌肝转移的临床效果[J]. 中国医药导报, 2020, 17(5): 95-98,103.
LU Ruimin1,2 LIU Tao2 WANG Xinji2 LI Jianguo2 LIANG Yao3 LUO Lijie1. Clinical effect of Cetuximab combined with FOLFOXIRI regimen in the treatment of liver metastasis of unresectable colorectal cancer. 中国医药导报, 2020, 17(5): 95-98,103.
2020, Vol. 17 
京公网安备 11010502046598号